Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Significant is the Anticipated Growth Rate of the Allogeneic T Cell Therapies Market from 2025 to 2034?

The market for allogeneic t cell therapies has witnessed fast-paced expansion in the past few years. Its value is set to increase from $1.16 billion in 2024 to $1.28 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 10.0%. Factors that contributed to the growth during the historical period include regulatory green lights, an uptick in cancer cases, an increase in clinical trials, governmental monetary support, and a rising older population.

In the upcoming years, a robust growth is anticipated in the allogeneic t cell therapies market, which is projected to reach $1.85 billion by 2029, growing at a compound annual growth rate (CAGR) of 9.8%. This growth across the forecast period can be credited to enhanced indications, escalating demand for cell-based immunotherapies, rising knowledge about progressive therapies, increased spending on healthcare, and encouraging reimbursement policies. Key trends for the forecast period encompass improvement in research and development activities, personalized medication, off-the-shelf therapies, expansion of the global market, strategic alliances, and the progressing regulatory landscape.

How Are the key drivers expanding the growth of the Allogeneic T Cell Therapies Market?

The escalating prevalence of cancer is anticipated to fuel the expansion of the allogeneic T cell therapies market. Cancer encompasses a variety of diseases typified by unrestrained proliferation and dissemination of abnormal cells throughout the body. The rise in cancer cases is driven by factors such as extended lifespan, changes in lifestyle, environmental exposure, infections, genetic predisposition, and shifts in reproductive patterns, leading to an increased incidence and detection of ailment. Allogeneic T cell therapies, which infuse genetically manipulated donor T cells discerning specific tumor antigens, are employed to combat and eliminate cancer cells in patients. For illustration, by May 2024, as per the National Cancer Institute, a governmental agency in the U.S, the count of cancer survivors was around 18.1 million. This number is anticipated to surge to 22.5 million by 2032. It is projected that by 2040, the annual count of new cancer cases will hit 29.9 million, and the number of cancer-related mortalities will climb to an estimated 15.3 million. Thus, the surge in cancer cases propels the allogeneic T cell therapies market.

Get Your Free Sample of the Global Allogeneic T Cell Therapies Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=18952&type=smp

Who Are the Dominant Players Pushing the Boundaries of the Allogeneic T Cell Therapies Market?

Major companies operating in the allogeneic t cell therapies market are Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Immatics NV, Sangamo Therapeutics Inc., Poseida Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Sorrento Therapeutics Inc., Autolus Therapeutics Plc, MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Enlivex Therapeutics Ltd., Cellectis SA, Adaptimmune Therapeutics Plc, Medigene AG, Celyad Oncology SA, Allogene Therapeutics Inc., Bellicum Pharmaceuticals Inc.

How Are Market Trends Revolutionizing the Allogeneic T Cell Therapies Industry in Recent Times?

Leading firms in the allogeneic T cell therapies market are concentrating their efforts on creating novel chimeric antigen receptor (CAR) T-cell therapy strategies, with the aim of improving treatment efficiency and broadening therapeutic alternatives. These innovative endeavors are advanced methods designed to boost the potency, availability, and administration of CAR T-cell treatments for cancer. For example, in October 2022, Allogene Therapeutics Inc., a biotechnology firm based in the US, unveiled CAR T Together, a ground-breaking initiative to tackle the issues related to the delivery and access of CAR T therapies. The scheme is centered on streamlining the procedure for clinical trial participation and promoting cooperation among oncologists to hasten the creation of allogeneic CAR T therapies. In contrast to autologous therapies that are tailored using the patient’s own cells, allogeneic therapies utilize T cells from healthy donors, allowing for more effective production processes.

Get Instant Access to the Global Allogeneic T Cell Therapies Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/allogeneic-t-cell-therapies-global-market-report

What Are the Key Components of the Allogeneic T Cell Therapies Market, and How Do Its Segments Perform?

The allogeneic t cell therapiesmarket covered in this report is segmented –

1) By Product Type: Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types

2) By Antigen Type: CD 19, CD 20, Egfrvlll, GD2, CD22, CD30, CD33, Meso, HER1, Other Antigen Types

3) By Therapeutics Indications: Cancer, Autoimmune Diseases, Infectious Diseases, Others Therapeutics Indications

4) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users

Subsegments:

1) By Chimeric Antigen Receptor (CAR) T Cell Therapies: CD19-targeted CAR T Therapies, BCMA-targeted CAR T Therapies, CD22-targeted CAR T Therapies

2) By T Cell Receptor (TCR) Therapies: Neoantigen-targeted TCR Therapies, Viral Antigen-targeted TCR Therapies

3) By Other Product Types: Engineered T Cell Therapies, NK Cell Therapies

Which Geographic Areas Are Influencing the Growth of the Allogeneic T Cell Therapies Market?

North America was the largest region in the allogeneic T cell therapies market in 2024. The regions covered in the allogeneic T cell therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Can We Define the Allogeneic T Cell Therapies Market and Its Key Components?

Allogeneic T cell therapies are a type of medical treatment where T cells, a crucial component of the immune system, are obtained from a donor (rather than the patient) and used to target and destroy cancer cells in the recipient. Allogeneic T-cell therapies are primarily used in the treatment of various cancers, particularly those that are difficult to treat with conventional methods.

Browse Through More Similar Reports By The Business Research Company:

Autologous Cell Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/autologous-cell-therapy-global-market-report

Cell and Gene Therapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

Cellular Immunotherapy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: